Zou Mengxiao, Xu Gang, Ge Shuwang, Guo Kanglin, Duo Qian, Cheng Yichun
Division of Internal Medicine, Department of Nephrology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Curr Pharm Des. 2025;31(9):730-740. doi: 10.2174/0113816128347345241028063515.
IgA nephropathy (IgAN) is the most prevalent primary glomerulonephritis globally and has a high propensity to develop into end-stage renal disease (ESRD). Hydroxychloroquine has been proven to reduce proteinuria in IgAN patients, but the precise mechanism remains unclear. Therefore, network pharmacology was used to investigate the mechanism.
PubChem and SwissADME databases were utilized to acquire the structure of hydroxychloroquine. The SwissTargetPrediction, PharmMapper, DrugBank, TargetNet, and BATMAN-TCM databases were then utilized to obtain the targets. The target genes related to IgAN were then gathered from the databases, which included GeneCards, PHARMGKB, DrugBank, OMIM, and DisGeNET. Common targets were obtained by UniProt. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to define the main molecular mechanisms and pathways. Furthermore, a protein-protein interaction (PPI) network was constructed using the STRING tool, and the core targets were obtained by Cytoscape. Finally, molecular docking between the core targets and hydroxychloroquine was performed.
167 common target genes were acquired by overlapping. The core targets were TNF, ALB, IL1B, JUN, FOS, SRC, and MMP9. The GO and KEGG results showed the targets to be related to the production of inflammatory cytokines and chemokines and were engaged in the toll-like receptor (TLR) signaling pathway. At the same time, the molecular docking results showed that the core targets all combined with hydroxychloroquine closely.
This study proved that hydroxychloroquine may treat IgAN through the TLR signaling pathway, and the restraint of TNF, TLR, IL1B, and JUN may be essential for the treatment.
IgA 肾病(IgAN)是全球最常见的原发性肾小球肾炎,且极易发展为终末期肾病(ESRD)。已证实羟氯喹可降低 IgAN 患者的蛋白尿,但确切机制仍不清楚。因此,本研究采用网络药理学来探究其机制。
利用 PubChem 和 SwissADME 数据库获取羟氯喹的结构。随后利用 SwissTargetPrediction、PharmMapper、DrugBank、TargetNet 和 BATMAN-TCM 数据库获取靶点。然后从 GeneCards、PHARMGKB、DrugBank、OMIM 和 DisGeNET 等数据库收集与 IgAN 相关的靶基因。通过 UniProt 获取共同靶点。进行基因本体论(GO)和京都基因与基因组百科全书(KEGG)富集分析以确定主要分子机制和途径。此外,使用 STRING 工具构建蛋白质 - 蛋白质相互作用(PPI)网络,并通过 Cytoscape 获取核心靶点。最后,对核心靶点与羟氯喹进行分子对接。
通过重叠获得 167 个共同靶基因。核心靶点为 TNF、ALB、IL1B、JUN、FOS、SRC 和 MMP9。GO 和 KEGG 结果表明这些靶点与炎性细胞因子和趋化因子的产生相关,并参与 Toll 样受体(TLR)信号通路。同时,分子对接结果表明核心靶点均与羟氯喹紧密结合。
本研究证明羟氯喹可能通过 TLR 信号通路治疗 IgAN,抑制 TNF、TLR、IL1B 和 JUN 可能是治疗的关键。